Sequenom Inc (SQNM)

2.39
0.01 0.42
NASDAQ : Health Care
Prev Close 2.40
Open 2.39
Day Low/High 2.39 / 2.40
52 Wk Low/High 0.00 / 0.00
Volume 2.05M
Avg Volume 2.19M
Exchange NASDAQ
Shares Outstanding 119.24M
Market Cap 284.99M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
AutoZone, General Motors, SanDisk Are Big Movers

AutoZone, General Motors, SanDisk Are Big Movers

AutoZone, General Motors, SanDisk, Dollar Tree among big market movers Wednesday

Sequenom Shares Rise On Lazard Analyst Comment

Sequenom shares gain ground as Lazard Capital Markets analyst upgrades, but maintains caution

Biotech Stock Mailbag: Sequenom, Vanda

Readers want to know what's next for Sequenom after the data mishandling debacle, and what the prognosis is for Vanda.

Surprising Approval for Vanda's Fanapt

Surprising Approval for Vanda's Fanapt

The approval of Vanda's drug Fanapt for schizophrenia by the Food and Drug Administration sent shares of the company leaping more than 800% in Wednesday's after-hours trading session.

Stock Search: Dendreon, Citigroup, Ford

Drug companies continued to lead the list of most-searched stocks.

Stock Search: Dendreon, Citigroup, Ford

Dendreon remains No. 1 on TheStreet.com's list of most-searched-for stocks, with Citigroup and Ford holding the No. 2 and No. 3 slots, respectively. New to today's list are Cell Therapeutics, Sequenom and GE.

Stocks End Day Mixed, but Rise for April

The major indices in New York closed mixed on Thursday, but they locked in solid gains for the month of April.

Kellogg, Kodak, MGM Mirage, Exxon Mobil Big Movers

Kellogg, Kodak, MGM Mirage, Exxon Mobil, Dow Chemical are big market movers Thursday

Sequenom Fallout Hits Hedge Funds

Investors are selling biotech stocks owned by two hedge funds that took highly concentrated positions in Sequenom on fears that they may be forced to liquidate their other holdings.

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

Sequenom Shares Plummet After Delay Of Downs Test

Sequenom tumbles after company says SEQureDx data is compromised and delays launch

Sequenom Tanks on Mishandled Data

Sequenom shares are plunging after the company said data for its Down syndrome test were mishandled.

Ahead Of The Bell: Sequenom Delays Downs Test

Sequenom tumbles after company says SEQureDx data is compromised and delays launch

Sequenom 1Q Loss Widens On Costs

Sequenom 1Q loss widens on higher costs from research and development programs

Sequenom Mulls Change to Down Syndrome Test

Sequenom is considering switching from an RNA-based screening method to one based on DNA for its Down syndrome test.

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

Analysts' Upgrades, Downgrades: Motorola

Analysts' Upgrades, Downgrades: Motorola

See who made what calls.

Biotech Stock Mailbag: My Say on Sequenom

Biotech Stock Mailbag: My Say on Sequenom

Travis T. takes umbrage with an article on Sequenom's latest Down syndrome data.

'Fast Money' Recap: Wall Street Bonus Uproar

'Fast Money' Recap: Wall Street Bonus Uproar

The trading panel discussed the controversy over the hefty bonuses in the banking industry.

Sequenom Still Very Good, Just No Longer Perfect

Sequenom Still Very Good, Just No Longer Perfect

The genetics-testing company said its experimental SEQureDx test recorded one false positive from a new batch of 459 blood samples collected from pregnant women at high risk for giving birth to a Down syndrome baby.

Genzyme, Exact Sciences Rise on Deal

Genzyme, Exact Sciences Rise on Deal

Under the deal, Genzyme will own intellectual property related to prenatal and reproductive health.

Biotech Stock Mailbag: Panacos

Biotech Stock Mailbag: Panacos

Panacos is worth more than 12 cents -- and is worth hanging on to.

Biotech Confab: First Look at Today's News

Biotech Confab: First Look at Today's News

Early news from the J.P. Morgan Healthcare conference involves Sequenom, Vertex, Humane Genome Sciences and others.

Buyers Need To Be Aggressive

Low volume is undermining the bullish message of the three-day rally. Quick action must be taken at new support.

Cramer's 'Mad Money' Recap: Looking at the Bright Side

Cramer says it's about time to start looking at the positive turns in the market.

Myriad Genetics' Meldrum Is Best In Biotech

Peter Meldrum Wins Swanson Trophy for pulling off one of the smartest drug licensing deals of all time.

Health Winners & Losers: Eli Lilly

The company launches its bid to take over ImClone.

Health Winners & Losers: Pfizer

Health Winners & Losers: Pfizer

Pfizer leads the losers on the Amex pharmaceutical index after announcing it plans to restructure into three business units.

Health Winners & Losers: ImClone

Health Winners & Losers: ImClone

ImClone shares were trading up on continuing talks about its mystery suitor.

Health Winners & Losers: Vertex

Health Winners & Losers: Vertex

The Nasdaq and Amex biotechnology indices are up 1.2% and 0.7%, respectively.